NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/11/2023
Back to search
Official data from USPTO
MOLECULAR CANCER THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MOLECULAR CANCER THERAPEUTICS
ST13
US500000097377394Class
16, 41
Filing
97377394
Registration
7104044
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
07/11/2023
Trademark type
Word
Nice classes
16, 41
Filing date
04/22/2022
Registration date
07/11/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/11/2023
Last transaction
07/11/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
10/30/2001
First use in commerce
10/30/2001
Drawing code
4
Owner type
99
Owner location
Philadelphia, PA
Examiner
WATTS-FITZGERALD, CAITLIN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
American Association of Cancer Research, Inc.
Representatives
Mark A. Steiner, Esq. DUANE MORRIS LLP
Technical classification
Nice Classes
Class 16Class 41
Vienna Codes
No Vienna codes available.
Goods and services
Class 16
Publicationsprinted journals in the field of medicine
Class 41
Online publicationsjournals in the field of medicine
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/25/2023
PUBO
PUBLISHED FOR OPPOSITION
04/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/22/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/20/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/20/2023
GNRT
NON-FINAL ACTION E-MAILED
03/20/2023
CNRT
NON-FINAL ACTION WRITTEN
03/20/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/23/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
02/21/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/03/2023
DOCK
ASSIGNED TO EXAMINER
02/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/28/2022
NWAP
NEW APPLICATION ENTERED
04/26/2022
Continuous trademark protection
Get notified about every new filing that threatens MOLECULAR CANCER THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.